Verteporfin
Other / unclassified targets YAP1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | VISUDYNE | — | 2001-08-22 – 2008-06-30 | fda.gov ↗ |
| Approved | EU (EMA) | Visudyne | — | 2000-07-27 | europa.eu ↗ |
| Approved | US (FDA) | VISUDYNE | — | 2000-04-12 | fda.gov ↗ |
Trials 45 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 17 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01325181 Comparator | Jul 2009 → Sep 2012 | central serous chorioretinopathy | Jang Won Heo | Completed | No outcome recorded |
| Phase 1/2 | NCT00138632 Background | Sep 2005 → Nov 2007 | wet macular degeneration | Novartis | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07488988 Comparator | Jun 2026 → Feb 2028 expected | — | Odense University Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT00546936 Comparator | Oct 2007 → Oct 2009 | histoplasmosis retinitis | Barnes Retina Institute | Unknown | No outcome recorded |
| Phase 2 | NCT00359164 Comparator | Jul 2006 → Jun 2008 | macular degeneration | University of British Columbia | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT01922102 Comparator | Sep 2013 → Sep 2016 | degenerative myopia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01482910 Comparator | Dec 2011 → Mar 2014 | macular degeneration | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01217944 Comparator | Oct 2010 → Aug 2012 | myopia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00967850 Comparator | Apr 2008 → Jun 2011 | choroidal neovascularization, myopia | Institute of Applied Ophthalmobiology - IOBA | Completed | No outcome recorded |
| Phase 3 | NCT01570608 Comparator | Mar 2007 → Aug 2011 | age-related macular degeneration | The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery | Completed | No outcome recorded |
| Phase 3 | NCT00370539 Background | Sep → Nov 2006 | wet macular degeneration | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT00242580 Background | Sep 2005 → Jan 2008 | age-related macular degeneration, choroidal neovascularization | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02072408 Background | Feb 2014 → Nov 2017 | ocular vascular disorder | Samsung Medical Center | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT03941587 Comparator | Feb 2021 → Jun 2024 | perifoveal exudative vascular anomalous complex | Singapore National Eye Centre | Completed | No outcome recorded |
| — | NCT01256580 Comparator | Aug 2010 → Mar 2013 | angioid streaks, central serous chorioretinopathy, choroidal neovascularization, histoplasmosis retinitis +3 | Massachusetts Eye and Ear Infirmary | Withdrawn | No outcome recorded |
| — | NCT01019668 Comparator | Nov 2008 → Dec 2009 | central serous chorioretinopathy | Shin Kong Wu Ho-Su Memorial Hospital | Completed | No outcome recorded |
| — | NCT00455871 Comparator | Apr 2007 → Oct 2010 | age-related macular degeneration | Barnes Retina Institute | Unknown | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 63 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Verteporfin | “This research study was designed to determine the effect on port wine stains (PWS) of liposomal benzoporphyrin derivative monoacid (BPD-MA) termed verteporfin by intravenous...” NCT00556946 ↗53“The purpose of this study is to report the treatment effect and safety of combined intravitreal bevacizumab (IVB) and photodynamic therapy (PDT) with verteporfin using a...” NCT00802126 ↗ “PDT involves the use of a photo-activated chemotherapeutic agent, benzoporphyrin derivative (verteporfin/Visudyne) given intravenously that when stimulated by non-thermal...” NCT02464761 ↗ “In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT standard fluence” NCT01968486 ↗ “Aflibercept dosage of 2mg in 0.05ml along with intravenous infusion of Verteporfin (6mg/m2)followed by laser light at a dosage of 25Joule/cm2” NCT03941587 ↗ “Verteporfin (6 mg/m2, Visudyne®; Novartis International AG, Basel, Switzerland) was injected intravenously with a standard 10-min infusion” NCT04429139 ↗ “Ranibizumab 0.5mg, combined with photodynamic therapy with Verteporfin (dosage per label)” NCT00680498 ↗ “Verteporfin photodynamic therapy acts through occluding newly formed vessels.” NCT00429962 ↗ “Rescue treatment: Verteporfin photodynamic therapy” NCT02072408 ↗ |
| Known as | BPD-MA | “This research study was designed to determine the effect on port wine stains (PWS) of liposomal benzoporphyrin derivative monoacid (BPD-MA) termed verteporfin by intravenous...” NCT00556946 ↗ |
| Known as | CL 318,952 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314346 ↗ |
| Known as | liposomal benzoporphyrin derivative monoacid | “This research study was designed to determine the effect on port wine stains (PWS) of liposomal benzoporphyrin derivative monoacid (BPD-MA) termed verteporfin by intravenous...” NCT00556946 ↗ |
| Known as | Verteporfin = Visudyne | “Verteporfin = Visudyne” NCT00359164 ↗ |
| Known as | Verteporfin for Injection | “Verteporfin for Injection (VFI), photosensitizing drug” NCT06807359 ↗ |
| Known as | Verteporfina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314346 ↗ |
| Known as | Verteporfine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314346 ↗ |
| Known as | VFI | “Verteporfin for Injection (VFI), photosensitizing drug” NCT06807359 ↗ |
| Known as | Visudyne | “PDT involves the use of a photo-activated chemotherapeutic agent, benzoporphyrin derivative (verteporfin/Visudyne) given intravenously that when stimulated by non-thermal...” NCT02464761 ↗17“Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1” NCT00570193 ↗ “Verteporfin (6 mg/m2, Visudyne®; Novartis International AG, Basel, Switzerland) was injected intravenously with a standard 10-min infusion” NCT04429139 ↗ “ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection” NCT01360151 ↗ “Verteporfin (which is marketed under the brand name Visudyne) is the photosensitizer.” NCT02872064 ↗ “combined with reduced-fluence verteporfin PDT (Visudyne®; Novartis)” NCT01256580 ↗ “Photodynamic Therapy (PDT) with Visudyne (verteporfin)” NCT00134667 ↗ “Verteporfin (Visudyne) Photodynamic Therapy (PDT)” NCT00390026 ↗ “Bevacizumab (Avastin), Verteporfin (Visudyne)” NCT00696592 ↗ “Visudyne® + PTK787, 500 mg/day” NCT00138632 ↗ “Visudyne (Verteporfin PDT)” NCT00574093 ↗ |
| Known as | Visudyne = verteporfin | “Visudyne = verteporfin” NCT00570193 ↗ |
| Action | Inhibit | “Its Local Inhibition With Verteporfin” NCT06944249 ↗ |
| Modality | Other / unclassified | “a photosensitizing agent in combination with laser” NCT00390026 ↗ |
| Route | Intravenous | “verteporfin (given intravenously)” NCT00049959 ↗ |
| Target | YAP1 | “The Role of YAP1 in Fibrosis Explored Through Its Local Inhibition With Verteporfin” NCT06944249 ↗ |